NEW YORK (GenomeWeb News) – Australian firm Proteome Systems said today that it has stopped developing a protein biomarker-based test for prostate cancer because “the project did not satisfy internal assessment hurdles.”
The company said that it recently validated data generated by Egenix, which demonstrated that there is an increased expression of human carcinoma antigen in cancerous versus non-cancerous prostate tissues. The proof of concept study was aimed at evaluating the possibility of using a protein biomarker that provides specific detection of HCA in a semen-based test for prostate cancer.
However, Proteome Systems said that bringing the assay to market “would require significant resources along with an extended development timeline.”
The firm has a collaboration with Becton Dickinson to develop protein biomarkers for tuberculosis diagnostic products and an alliance with Bayer CropScience to use the firm’s DiagnostIQ device in defined agricultural fields.